NEW YORK – PixCell Medical announced Tuesday that it has partnered with in vitro diagnostics company Aidian to distribute PixCell's point-of-care hematology analyzer in certain countries in Europe.
Finland-based Aidian will have exclusive distribution rights to PixCell's HemoScreen analyzer in Finland, Norway, Denmark, Latvia, and Estonia. Additional terms of the deal were not disclosed.
The HemoScreen complete blood count analyzer is cleared by the US Food and Drug Administration and has received CE marking and uses a disposable cartridge with all necessary reagents to run CBC tests, the company said in a statement. It requires one drop of blood and returns results with 20 standard CBC parameters and abnormal cell flagging within six minutes.
The analyzer uses viscoelastic focusing to produce highly accurate measurements and image-based analysis of cell characteristics and requires a lower reagent volume than other standard cell counters, Yokneam, Israel-based PixCell said.
Last month, PixCell announced a Swedish distribution agreement with Triolab for the analyzer.